EGFR and cancer: CL and basal tumors are also distinguished by the expression of several pathway activation signatures; for examples, basal cancers displayed higher activity of MYC and PI3K pathways as already reported [60, 61], whereas CL tumors showed higher activity of EGFR, SRC and TGFβ pathways as reported by others [7] with therapeutic possibilities.